Weight gain is a frequent reason for discontinuing the contraceptive with depot-medroxyprogesterone acetate (DMPA).
Study design
This 3-year retrospective cohort study assessed body mass index (BMI; kg/m(2)) variations in 379 current or past DMPA users compared to TCu380A intrauterine device (IUD) users matched for age and BMI, categorized into G1 (normal weight), G2 (overweight) or G3 (obese) according to baseline BMI. Variations in weight and BMI were evaluated using analysis of variance.
Results
BMI increased progressively in all groups but significantly more in G1 and G2 DMPA users compared to nonusers and according to duration of use. In the G3 subgroup, weight trends were similar in the DMPA and IUD users.
Conclusions
Normal and overweight women increased BMI with DMPA use; however, obese women did not increase weight. Weight increase in DMPA users could be associated with metabolic alterations related to duration of use in normal and overweight women and to alterations already present in obese women. Prospective studies are required to determine triggering factors. DMPA use <or=3 years was not associated with weight increase in women with BMI (kg/m(2)) >or=30.
depo provera weight gain body mass index, dmpa contraceptive weight changes over time, depot medroxyprogesterone acetate obesity, birth control shot weight gain by bmi, contraceptive injection weight increase normal weight, dmpa metabolic effects overweight women, depo shot versus iud weight comparison, progesterone injection weight trends obese women, injectable contraception body weight changes, medroxyprogesterone acetate discontinuation weight gain
Cite this article
Pantoja, M., Medeiros, T., Baccarin, M. C., Morais, S. S., Bahamondes, L., & Fernandes, A. M. (2010). Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. *Contraception*, *81*(2), 107-111. https://doi.org/10.1016/j.contraception.2009.07.008
Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception. 2010;81(2):107-111. doi:10.1016/j.contraception.2009.07.008
Pantoja, M., et al. "Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive." *Contraception*, vol. 81, no. 2, 2010, pp. 107-111.
Objectives: Studies have demonstrated an association between hormonal contraception use with subsequent depression and antidepressant use. This association has not been assessed among postpartum women...
ObjectivesThe potential effect of hormonal contraception on HIV-1 acquisition and transmission represents an important public health issue. Several observational studies have suggested an association ...
Objective: As the HIV/AIDS epidemic continues to spread in Africa and Asia, use of the injectable contraceptive steroid DMPA is widespread and has been increasing. Since studies dating back to 1992 ha...
Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to infections such as HIV-1, unlike the injectable contraceptive norethisterone en...
Contraception/Comparison > FABM vs Hormonal > Side EffectsReproductive Endocrinology > Progesterone > Clinical EffectsContraception/Comparison > Side Effects > Hormonal Contraception